Author of

• 30943

  +

  P2.04 - Immuno-oncology (ID 167)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Immuno-oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 30964

    +

    P2.04-21 - Serum CRP Decrease Has Predictive Value for Long-Term Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC (ID 305)

    10:15 - 18:15  |  Author(s): Koji Sakamoto
    • Abstract

    Background
    

    Several studies showed the predictive or prognostic value of systemic inflammatory markers such as C-reactive protein (CRP) in patients with non-small cell lung cancer (NSCLC) treated with PD-1/PD-L1 inhibitors. In OAK study, serum CRP decrease at 6 weeks from baseline was associated with the favorable clinical efficacy of atezolizumab, a PD-L1 inhibitor. However, the result is not validated in the clinical practice setting including patients treated with anti PD-1 antibodies. The aim of this study is to investigate the significance of serum CRP change from baseline as a biomarker in NSCLC patients treated with PD-1/PD-L1 inhibitors.

    Method
    

    The current study is a retrospective cohort study. NSCLC patients treated with anti-PD-1/PD-L1 inhibitors in 2nd or later line setting were reviewed at Nagoya University Hospital and Tosei General Hospital. Patients were divided into two groups by serum CRP change (Group 1; patients with serum CRP decrease at 6 weeks by >= 33% compared to the baseline, and Group 2; the others except Group 1).

    Result
    

    From January 2016 to September 2018, 124 advanced or recurrent NSCLC patients were enrolled. 34 (27.4%) patients were divided into Group 1 and 90 (72.6%) were into group 2, respectively. Group 1 showed statistically significant higher objective response rate compared with Group 2 (38.2% vs 7.0%, p< 0.01), and longer progression-free survival (PFS) (1-year PFS rate: 34.2% vs. 11.7%, HR of group 1 to group 2: 0.63 (95%CI: 0.39-0.98), p=0.04). Multivariate analysis also identified the CRP decrease as an independent favorable factor of PFS (adjusted HR of group 1 to group 2: 0.45 (95%CI: 0.26-0.77), p< 0.01). In contrast, PFS and OS were similar between the patients treated with PD-1 and PD-L1 inhibitors.

    Conclusion
    

    Serum CRP decrease at 6 weeks from baseline would have predictive value for long-term disease control by PD-1/PD-L1 inhibitors for NSCLC in the clinical practice setting.